Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. reports developments in model-informed drug development, combining biosimulation software, technology and services for drug discovery, clinical development and regulatory science. Company news frequently centers on quarterly results, revenue mix between software and services, guidance updates and operating changes following the completed divestiture of its global medical writing and related regulatory services business.
Recurring updates also cover strategic partnerships with drug-development service providers and the use of Certara's Simcyp® Simulator for physiologically based pharmacokinetic modeling. These announcements describe biosimulation applications in clinical pharmacology, new drug applications and regulatory decision-making for biopharmaceutical, academic and agency clients.
Certara (Nasdaq:CERT) reported Q1 2026 revenue of $106.9 million, up 1% year over year. Software revenue rose 7% to $49.7 million, while services revenue fell 4% to $57.2 million.
The company posted a net loss of $8.8 million (‑$0.06 per share) versus prior-year net income of $4.7 million. Adjusted EBITDA was $31.7 million and adjusted net income was $14.5 million.
Certara completed the sale of its global medical and regulatory writing business to Veristat for $85 million cash, $15 million escrow, and up to $35 million in earn‑out. Updated 2026 guidance calls for revenue of $395–$405 million and adjusted EBITDA margin of 30%–32%.
Altasciences and Certara (Nasdaq: CERT) announced a strategic partnership on May 7, 2026 to integrate Certara's model-informed drug development (MIDD) and biosimulation into Altasciences' Acceleration Platform.
The collaboration aims to establish proof of mechanism earlier, optimize study designs and dosing, embed modeling into execution, and support faster go/no-go decisions across nonclinical, clinical, bioanalysis, and manufacturing workflows.
Certara (Nasdaq: CERT) agreed to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, with closing expected in Q2 2026 subject to customary conditions.
In 2025 the unit generated $50 million revenue and $17 million adjusted EBITDA and includes ~220 employees. Certara will update 2026 guidance upon close and intends to deploy proceeds to advance its MIDD and Clinical Intelligence strategy.
Certara (Nasdaq: CERT) will report first quarter 2026 financial results before market open on Monday, May 11, 2026. Management will host a conference call at 8:30 AM ET to discuss results; registration is required and early registration is recommended. A live and archived webcast will be available in the Investors section of the Certara website.
Certara (Nasdaq: CERT) said its Simcyp Simulator PBPK modeling was accepted by the U.S. FDA in lieu of clinical studies to support the NDA for asciminib (Scemblix) for chronic myeloid leukemia. The modeling reportedly replaced at least ten dedicated clinical pharmacology studies and characterized asciminib pharmacokinetics across healthy volunteers and cancer patients.
The simulations bridged tested and untested scenarios, assessed drug–drug interactions, and supported dosing-regimen evaluation, reflecting a decade-long modeling effort and regulatory acceptance that reduced clinical study needs and development time.
Certara (Nasdaq: CERT) said management will participate in three investor conferences in early March 2026: TD Cowen on March 3 at 3:10PM ET, Leerink Global Healthcare on March 9 at 8:00AM ET, and Barclays Global Healthcare on March 10 at 1:00PM ET.
Live webcasts will be available on Certara’s investor relations website and replays will be accessible for at least 90 days.
Certara (Nasdaq: CERT) reported FY2025 revenue of $418.8M (9% growth) and adjusted EBITDA of $134.5M (10% growth). Q4 2025 revenue was $103.6M (+3%) with adjusted EBITDA of $32.5M (down 3%) and a Q4 net loss of $5.9M. Management named Jon Resnick CEO effective Jan 1, 2026. For full-year 2026 the company guides revenue growth of 0–4%, adjusted EBITDA margin of 30–32%, adjusted diluted EPS of $0.44–$0.48, and fully diluted shares of 160–162M.
Q4 bookings were $155.2M (+7%) including services bookings of $99.1M (+17%). The company cited higher operating expenses in Q4 driven by employee costs and refinancing-related transaction expenses.
Certara (NASDAQ:CERT) will release fourth quarter and full year 2025 financial results before market open on February 26, 2026. Management will host a conference call to discuss results at 8:30 AM ET. Investors must register online and are advised to register at least one day early. A live and archived webcast will be available in the Investors section of Certara's website.
Certara (Nasdaq: CERT) appointed Jon Resnick as Chief Executive Officer and board member effective January 1, 2026, succeeding William F. Feehery, who will step down as CEO on December 31, 2025 and serve as an external advisor during the transition. Resnick brings over 20 years of life‑sciences leadership at IQVIA, including service as President of the U.S. and Canada region since 2019.
The board thanked Feehery for guiding Certara through its IPO and software investments. The company also reaffirmed its full‑year 2025 financial outlook as previously disclosed on November 6, 2025.
Certara (Nasdaq: CERT) reported third quarter 2025 results: revenue $104.6M (+10% YoY), software revenue $43.8M (+22% YoY; organic software +6%), and services revenue $60.8M (+3% YoY). Net income was $1.5M versus a $1.4M loss a year earlier; diluted EPS was $0.01. Adjusted EBITDA was $35.2M (+7% YoY) and adjusted net income was $22.2M (+$2.0M YoY). Bookings totaled $96.6M (+1% YoY) with software bookings $40.8M (+17%) and services bookings $55.8M (−9%).
The company narrowed and raised full-year 2025 guidance to $415M–$420M revenue, target ~32% adjusted EBITDA margin, and $0.45–$0.47 adjusted diluted EPS with fully diluted shares of 160M–162M.